Skip to main content
iPSC line to identify novel therapies for ARVC

iPSC line to identify novel therapies for ARVC

Technology Duke inventors have developed a novel induced pluripotent stem cell (iPSC) line that contains a mutation that impacts the TAX1BP3 gene, which causes arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC). Specifically, the iPSCs were derived from…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us